| Market Cap | 767.54M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -65.7M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -2.00% |
| Sales | 3.33M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -3.00% |
| Dividend | N/A | Price/Book | 1.43 | EPS next 5Y | - | 52W High Chg | -25.00% |
| Recommedations | 1.00 | Quick Ratio | 6.64 | Shares Outstanding | 270.41M | 52W Low Chg | 29.00% |
| Insider Own | 14.56% | ROA | -13.09% | Shares Float | 153.55M | Beta | 0.93 |
| Inst Own | 78.39% | ROE | -13.25% | Shares Shorted/Prior | -/- | Price | 2.78 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 6,059 | Target Price | 3.50 |
| Oper. Margin | -38,910.00% | Earnings Date | Apr 25 | Volume | 15 | Change | 0.00% |
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.